English
|
Español
English
|
Español
Insurance
Marketing
Pharmaceuticals
Technology/Innovation
Regulatory
Community
Johnson & Johnson
Press release submission
| May 21, 2021
RYBREVANT™ (amivantamab-vmjw) Receives FDA Approval as the First Targeted Treatment for Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
Press release submission
| Dec 20, 2019
JOHNSON & JOHNSON: Acquires TARIS Biomedical with Focus on Transforming the Treatment of Bladder Cancer
Press release submission
| Jun 14, 2019
JOHNSON & JOHNSON: Janssen reports top-line Phase 3 results for TREMFYA® (guselkumab) in adults with active psoriatic arthritis
Trending
Patient Daily
| Aug 12, 2025
Capitol Breathe Free Otolaryngologist on air quality and pollution: ‘These are common triggers for sinus inflammation and sinus infections’
+
Pharmaceuticals
Patient Daily
| Aug 18, 2025
Patients Come First spokesperson on 340B rebate model: ‘This rebate model provides the oversight that 340B has needed for decades’
+
Regulatory
Patient Daily
| Aug 14, 2025
Founder of Policy Candy: '340B must see comprehensive reforms'
+
Pharmaceuticals
Patient Daily
| Aug 14, 2025
PhRMA COO on 340B: 'Hidden tax on patients, taxpayers & employers'
